Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Durvalumab

Immunology

Immunology Today—March 18, 2026

This week’s Immunology update highlights regulatory progress, late-stage…

Immunology

Immunology Video Recap—February 11, 2026

This biweekly Immunology video recap summarizes key regulatory actions,…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics
Lucid Diligence Brief: AstraZeneca’s tozorakimab meets primary endpoint in COPD
Lucid Diligence Brief: Pinnacle Medicines $89 million Series B
Respiratory Today—March 27, 2026
Vaccines Today—March 27, 2026

Tags

AHA 2025 AtriCure Bluejay Therapeutics Canada National Strategy for Drugs for Rare Diseases cancer care cancer vaccines CAR-NK therapy CB1 pathway Celcuity China risk competitive advantage Coronary artery calcium Dapiglutide depemokimab Doctronic EADV 2025 EGFR-mutated non-small cell lung cancer ENHANZE G6PD deficiency GPCR Healthcare Policy HeartFlow hepatitis D icddr b infantile hemangioma Lilly ExploR&D Menkes disease Minimally invasive surgery mitapivat Monoclonal antibodies mRNA therapeutics Myocarditis neuroinflammatory diseases Nipocalimab nitrous oxide Pain pediatric urology Prurigo nodularis Rare blood disorders Samsung Bioepis SK Pharmteco Tecvayli Tessera Therapeutics Venous thromboembolism Zaire Ebola Vaccine

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics
Lucid Diligence Brief: AstraZeneca’s tozorakimab meets primary endpoint in COPD
Lucid Diligence Brief: Pinnacle Medicines $89 million Series B
Respiratory Today—March 27, 2026
Vaccines Today—March 27, 2026

TAGS

AHA 2025 AtriCure Bluejay Therapeutics Canada National Strategy for Drugs for Rare Diseases cancer care cancer vaccines CAR-NK therapy CB1 pathway Celcuity China risk competitive advantage Coronary artery calcium Dapiglutide depemokimab Doctronic EADV 2025 EGFR-mutated non-small cell lung cancer ENHANZE G6PD deficiency GPCR Healthcare Policy HeartFlow hepatitis D icddr b infantile hemangioma Lilly ExploR&D Menkes disease Minimally invasive surgery mitapivat Monoclonal antibodies mRNA therapeutics Myocarditis neuroinflammatory diseases Nipocalimab nitrous oxide Pain pediatric urology Prurigo nodularis Rare blood disorders Samsung Bioepis SK Pharmteco Tecvayli Tessera Therapeutics Venous thromboembolism Zaire Ebola Vaccine

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy